Antiangiogenic agent

This page covers all Antiangiogenic agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF.

Targets

VEGF

Phase 3 pipeline (1)

• VB-111 + bevacizumab · Vascular Biogenics Ltd. operating as VBL Therapeutics · Oncology
  VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF.